This is the authors' abstract. We don't add key points for this paper.
Introduction The direction of the causal link between solid cancers and elevated plasma vitamin B₁₂ (B₁₂) remains uncertain. Material and methods We retrospectively included patients having two B₁₂ measurements with a B₁₂ initially ≥ 1000 ng/l and a solid cancer diagnosed between the measurements. Patients were included in the Curative or Supportive group according to their treatments. Results B₁₂ changes over time differed among groups (p = 0.001): +157.4 ng/L/month in the Supportive care group versus -171.6 ng/L/month in the Curative care group. Conclusions The decrease of plasma B₁₂ in cases of curative care could suggest that this B₁₂ elevation is secondary to solid cancers.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lacombe et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: